Skip to main content
PMC home page
Gut logoLink to Gut
. 1997 Jun;40(6):761–766. doi: 10.1136/gut.40.6.761

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.

S Schreiber 1, J Hämling 1, E Zehnter 1, S Howaldt 1, W Daerr 1, A Raedler 1, W Kruis 1
PMCID: PMC1027201  PMID: 9245930

Abstract

BACKGROUND: An increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid. AIM: In a point prevalence study the occurrence of sensitive indices indicative of early kidney malfunction was assessed in outpatients with inflammatory bowel disease. METHODS: Routine indices of kidney function (creatinine clearance, urinary protein content, pH, electrolytes, and microscopy) were investigated in 223 patients with inflammatory bowel disease as well as sensitive markers of glomerular or tubular dysfunction (microproteinuria by SDS polyacrylamide gel electrophoresis (SDS-PAGE), urinary concentrations of N-acetyl-beta-D-glucosaminidase, alpha 1-microglobulin, gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), and albumin). Histories of exposure to 5-ASA were assessed by questionnaire. RESULTS: Patients receiving high amounts of 5-ASA, both actual as well as on a lifetime basis, showed an increased prevalence of tubular proteinuria by SDS-PAGE. Raised values for urinary AP and GGT indicate proximal tubular epithelial cells as the source. All other kidney function tests were normal. Analysis of covariates indicated strong associations between disease activity and size of 5-ASA doses as well as alterations in kidney tubular function. CONCLUSION: The possibility exists that high doses of 5-ASA may be associated with proximal tubular proteinuria. This point prevalence study cannot dissect the possible impact of chronic inflammation from high dose 5-ASA treatment and further prospective studies are warranted.

Full text

PDF
761

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRANDER L., KUHLBACK B., NIEMISTO M., RISKA N. The effect of massive doses of PAS on renal function and electrolyte balance. Scand J Clin Lab Invest. 1963;15 (Suppl 69):38–43. [PubMed] [Google Scholar]
  2. Best W. R., Becktel J. M., Singleton J. W., Kern F., Jr Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976 Mar;70(3):439–444. [PubMed] [Google Scholar]
  3. Best W. R., Becktel J. M., Singleton J. W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979 Oct;77(4 Pt 2):843–846. [PubMed] [Google Scholar]
  4. Brezin J. H., Katz S. M., Schwartz A. B., Chinitz J. L. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1979 Dec 6;301(23):1271–1273. doi: 10.1056/NEJM197912063012306. [DOI] [PubMed] [Google Scholar]
  5. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 1972 Jan 15;1(5793):152–154. doi: 10.1136/bmj.1.5793.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Christensen L. A., Fallingborg J., Abildgaard K., Jacobsen B. A., Sanchez G., Hansen S. H., Bondesen S., Hvidberg E. F., Rasmussen S. N. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990 Oct;4(5):523–533. doi: 10.1111/j.1365-2036.1990.tb00499.x. [DOI] [PubMed] [Google Scholar]
  7. Clive D. M., Stoff J. S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984 Mar 1;310(9):563–572. doi: 10.1056/NEJM198403013100905. [DOI] [PubMed] [Google Scholar]
  8. Diener U., Tuczek H. V., Fischer C., Maier K., Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(3):278–282. doi: 10.1007/BF00505331. [DOI] [PubMed] [Google Scholar]
  9. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dubach U. C., Rosner B., Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med. 1983 Feb 17;308(7):357–362. doi: 10.1056/NEJM198302173080703. [DOI] [PubMed] [Google Scholar]
  11. Gabriel R. Time to scrap creatinine clearance? Br Med J (Clin Res Ed) 1986 Nov 1;293(6555):1119–1120. doi: 10.1136/bmj.293.6555.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hanauer S. B., Krawitt E. L., Robinson M., Rick G. G., Safdi M. A. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep;88(9):1343–1351. [PubMed] [Google Scholar]
  13. Isaacs K. L., Sartor R. B., Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992 Nov;103(5):1587–1595. doi: 10.1016/0016-5085(92)91182-4. [DOI] [PubMed] [Google Scholar]
  14. Kreisel W., Wolf L. M., Grotz W., Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996 May;8(5):461–468. [PubMed] [Google Scholar]
  15. Lemann J., Jr, Doumas B. T. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. Clin Chem. 1987 Feb;33(2 Pt 1):297–299. [PubMed] [Google Scholar]
  16. Lockwood T. D., Bosmann H. B. The use of urinary N-acetyl-beta-glucosaminidase in human renal toxicology. II. Elevation in human excretion after aspirin and sodium salicylate. Toxicol Appl Pharmacol. 1979 Jun 30;49(2):337–345. doi: 10.1016/0041-008x(79)90258-8. [DOI] [PubMed] [Google Scholar]
  17. MacDonald T. T., Hutchings P., Choy M. Y., Murch S., Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990 Aug;81(2):301–305. doi: 10.1111/j.1365-2249.1990.tb03334.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mahida Y. R., Wu K., Jewell D. P. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut. 1989 Jun;30(6):835–838. doi: 10.1136/gut.30.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mahmud N., O'Connell M. A., Stinson J., Goggins M. G., Weir D. G., Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995 Mar;7(3):215–219. [PubMed] [Google Scholar]
  20. Mahmud N., Stinson J., O'Connell M. A., Mantle T. J., Keeling P. W., Feely J., Weir D. G., Kelleher D. Microalbuminuria in inflammatory bowel disease. Gut. 1994 Nov;35(11):1599–1604. doi: 10.1136/gut.35.11.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mehta R. P. Acute interstitial nephritis due to 5-aminosalicylic acid. CMAJ. 1990 Nov 15;143(10):1031–1032. [PMC free article] [PubMed] [Google Scholar]
  22. Miner P., Hanauer S., Robinson M., Schwartz J., Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb;40(2):296–304. doi: 10.1007/BF02065413. [DOI] [PubMed] [Google Scholar]
  23. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Payne R. B. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem. 1986 May;23(Pt 3):243–250. doi: 10.1177/000456328602300304. [DOI] [PubMed] [Google Scholar]
  25. Pesce A. J., Boreisha I., Pollak V. E. Rapid differentiation of glomerular and tubular proteinuria by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Clin Chim Acta. 1972 Aug;40(1):27–34. doi: 10.1016/0009-8981(72)90247-1. [DOI] [PubMed] [Google Scholar]
  26. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989 Jan 14;298(6666):82–86. doi: 10.1136/bmj.298.6666.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  28. Riley S. A., Lloyd D. R., Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992 Oct;33(10):1348–1352. doi: 10.1136/gut.33.10.1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ruf-Ballauf W., Hofstädter F., Krentz K. Akute interstitielle Nephritis durch 5-Aminosalicylsäure? Internist (Berl) 1989 Apr;30(4):262–264. [PubMed] [Google Scholar]
  30. Sachar D. B. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol. 1995 Mar;20(2):117–122. doi: 10.1097/00004836-199503000-00009. [DOI] [PubMed] [Google Scholar]
  31. Scherberich J. E., Mondorf W. A. Beurteilung der Nephrotoxizität von Pharmaka über die Ausscheidung tubulusspezifischer Membranantigene und Enzyme. Z Gesamte Inn Med. 1983 Nov 1;38(21):571–580. [PubMed] [Google Scholar]
  32. Schreiber S., Heinig T., Thiele H. G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995 May;108(5):1434–1444. doi: 10.1016/0016-5085(95)90692-4. [DOI] [PubMed] [Google Scholar]
  33. Schreiber S., Raedler A., Conn A. R., Rombeau J. L., MacDermott R. P. Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut. 1992 Feb;33(2):236–241. doi: 10.1136/gut.33.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schwab S. J., Christensen R. L., Dougherty K., Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987 May;147(5):943–944. [PubMed] [Google Scholar]
  35. Singleton J. W., Hanauer S. B., Gitnick G. L., Peppercorn M. A., Robinson M. G., Wruble L. D., Krawitt E. L. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May;104(5):1293–1301. doi: 10.1016/0016-5085(93)90337-c. [DOI] [PubMed] [Google Scholar]
  36. Singleton J. W., Law D. H., Kelley M. L., Jr, Mekhjian H. S., Sturdevant R. A. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 1979 Oct;77(4 Pt 2):870–882. [PubMed] [Google Scholar]
  37. Staerk Laursen L., Stokholm M., Bukhave K., Rask-Madsen J., Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990 Nov;31(11):1271–1276. doi: 10.1136/gut.31.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stevens C., Walz G., Singaram C., Lipman M. L., Zanker B., Muggia A., Antonioli D., Peppercorn M. A., Strom T. B. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992 Jun;37(6):818–826. doi: 10.1007/BF01300378. [DOI] [PubMed] [Google Scholar]
  39. von Mühlendahl K. E. Nephritis durch 5-Aminosalicylsäure. Dtsch Med Wochenschr. 1989 Feb 10;114(6):236–236. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES